Scarica l'app Stockscreener
87.27
0.11%
-0.0524
Precedente Chiudi:
$87.22
Aprire:
$87.91
Volume 24 ore:
40,926
Relative Volume:
0.08
Capitalizzazione di mercato:
$4.72B
Reddito:
$144.75M
Utile/perdita netta:
$-53.89M
Rapporto P/E:
-22.04
EPS:
-3.96
Flusso di cassa netto:
$-42.88M
1 W Prestazione:
-8.37%
1M Prestazione:
-3.50%
6M Prestazione:
+63.54%
1 anno Prestazione:
+68.28%
Intervallo 1D:
$86.51
$88.72
Intervallo di 1 settimana:
$83.69
$94.99
Portata 52W:
$46.42
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Nome
Arcellx Inc
Settore
Industria
Telefono
240-327-0603
Indirizzo
800 BRIDGE PARKWAY, REDWOOD CITY
Confronta ACLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ACLX | 86.51 | 4.72B | 144.75M | -53.89M | -42.88M | -3.96 |
| VRTX | 445.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 737.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.21 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-04 | Reiterato | Needham | Buy |
| 2023-12-19 | Iniziato | Scotiabank | Sector Outperform |
| 2023-10-30 | Iniziato | TD Cowen | Outperform |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-05-18 | Iniziato | Truist | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-14 | Iniziato | Stifel | Buy |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-13 | Ripresa | BofA Securities | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-27 | Iniziato | Needham | Buy |
| 2022-07-20 | Iniziato | Canaccord Genuity | Buy |
| 2022-03-01 | Iniziato | BofA Securities | Buy |
| 2022-03-01 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Arcellx Inc Borsa (ACLX) Ultime notizie
(ACLX) Proactive Strategies - Stock Traders Daily
arcellx CFO Michelle Gilson sells $156,508 in shares By Investing.com - Investing.com Canada
arcellx CFO Michelle Gilson sells $156,508 in shares - Investing.com India
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? - MSN
First Turn Management LLC Makes New Investment in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Position Reduced by Victory Capital Management Inc. - MarketBeat
First Week of January 2025 Options Trading For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Arcellx (NASDAQ:ACLX) Shares Down 6.4%What's Next? - MarketBeat
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ar - GuruFocus.com
Perceptive Advisors LLC Adjusts Position in Arcellx Inc - GuruFocus.com
arcellx director Kavita Patel sells $159,495 in stock - Investing.com
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice - Yahoo Finance
FMR LLC Adjusts Stake in Arcellx Inc - GuruFocus.com
arcellx CFO Michelle Gilson sells $1.24 million in stock By Investing.com - Investing.com South Africa
Arcellx director Kavita Patel sells $5.97 million in stock - Investing.com
arcellx CFO Michelle Gilson sells $1.24 million in stock - Investing.com
Arcellx director Kavita Patel sells $5.97 million in stock By Investing.com - Investing.com UK
US Bancorp DE Acquires 2,851 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - Defense World
Objective long/short (ACLX) Report - Stock Traders Daily
Piper Sandler Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Arcellx Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
HC Wainwright Has Optimistic Outlook of Arcellx Q3 Earnings - Defense World
Analyst Expectations For Arcellx's Future - Benzinga
Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcellx (NASDAQ:ACLX) Hits New 1-Year High on Analyst Upgrade - Defense World
Arcellx earnings missed by $0.14, revenue fell short of estimates - Investing.com UK
HC Wainwright Estimates Arcellx's Q3 Earnings (NASDAQ:ACLX) - MarketBeat
HC Wainwright Boosts Arcellx (NASDAQ:ACLX) Price Target to $95.00 - Defense World
Needham & Company LLC Reiterates Buy Rating for Arcellx (NASDAQ:ACLX) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Bank of America Raises Arcellx (NASDAQ:ACLX) Price Target to $100.00 - Defense World
Arcellx : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q) - Marketscreener.com
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? - MSN
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcellx stock soars to all-time high of $97.61 amid robust growth - Investing.com India
Arcellx (NASDAQ:ACLX) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Arcellx (ACLX) Releases Clinical Data from Phase 1 and iMMagine-1 Studies for Multiple Myeloma Patients On November 5, 2024, Arcellx, Inc. (NASDAQ: ACLX) made public an abstract containing fresh clinical data from its Phase 1 and iMMagine-1 - Defense World
Arcellx price target raised to $106 from $81 at Morgan Stanley - Yahoo Finance
How Arcellx (ACLX) Stock Stands Out in a Strong Industry - MSN
ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti - Citeline News & Insights
Arcellx stock target increased, rating held on positive trial data - Investing.com
Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat
Arcellx (NASDAQ:ACLX) Price Target Raised to $100.00 - MarketBeat
Arcellx (NASDAQ:ACLX) Price Target Raised to $106.00 at Morgan Stanley - MarketBeat
Robert W. Baird Issues Positive Forecast for Arcellx (NASDAQ:ACLX) Stock Price - MarketBeat
HC Wainwright Increases Arcellx (NASDAQ:ACLX) Price Target to $95.00 - MarketBeat
Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma - BioSpace
Arcellx shares target upgraded, maintains buy on positive trial data By Investing.com - Investing.com South Africa
Arcellx Inc Azioni (ACLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):